Moreover, the 36-month beta value for RLAY is 1.60. Analysts have varying opinions on the stock, with 7 analysts rating it as a “buy,” 5 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for RLAY is 127.17M and currently, short sellers hold a 12.42% of that float. On March 12, 2025, RLAY’s average trading volume was 2.33M shares.
RLAY) stock’s latest price update
The stock of Relay Therapeutics Inc (NASDAQ: RLAY) has increased by 6.12 when compared to last closing price of 3.27. Despite this, the company has experienced a 8.78% gain in its stock price over the last five trading sessions. zacks.com reported 2025-03-05 that The heavy selling pressure might have exhausted for Relay Therapeutics (RLAY) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
RLAY’s Market Performance
RLAY’s stock has risen by 8.78% in the past week, with a monthly drop of -17.77% and a quarterly drop of -18.93%. The volatility ratio for the week is 8.80% while the volatility levels for the last 30 days are 8.51% for Relay Therapeutics Inc The simple moving average for the last 20 days is -4.91% for RLAY stock, with a simple moving average of -42.11% for the last 200 days.
Analysts’ Opinion of RLAY
Many brokerage firms have already submitted their reports for RLAY stocks, with Jefferies repeating the rating for RLAY by listing it as a “Buy.” The predicted price for RLAY in the upcoming period, according to Jefferies is $16 based on the research report published on September 10, 2024 of the previous year 2024.
Goldman, on the other hand, stated in their research note that they expect to see RLAY reach a price target of $20. The rating they have provided for RLAY stocks is “Buy” according to the report published on September 10th, 2024.
RLAY Trading at -16.50% from the 50-Day Moving Average
After a stumble in the market that brought RLAY to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -67.63% of loss for the given period.
Volatility was left at 8.51%, however, over the last 30 days, the volatility rate increased by 8.80%, as shares sank -13.47% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -17.97% lower at present.
During the last 5 trading sessions, RLAY rose by +8.78%, which changed the moving average for the period of 200-days by -54.10% in comparison to the 20-day moving average, which settled at $3.65. In addition, Relay Therapeutics Inc saw -15.78% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at RLAY starting from Patel Sanjiv, who sale 140,182 shares at the price of $3.85 back on Feb 11 ’25. After this action, Patel Sanjiv now owns 625,948 shares of Relay Therapeutics Inc, valued at $539,701 using the latest closing price.
Patel Sanjiv, the President and CEO of Relay Therapeutics Inc, sale 75,324 shares at $3.70 during a trade that took place back on Feb 13 ’25, which means that Patel Sanjiv is holding 883,089 shares at $278,699 based on the most recent closing price.
Stock Fundamentals for RLAY
Current profitability levels for the company are sitting at:
- -38.54 for the present operating margin
- 0.72 for the gross margin
The net margin for Relay Therapeutics Inc stands at -33.75. The total capital return value is set at -0.47. Equity return is now at value -44.15, with -39.38 for asset returns.
Based on Relay Therapeutics Inc (RLAY), the company’s capital structure generated 0.06 points at debt to capital in total, while cash flow to debt ratio is standing at -5.14.
Currently, EBITDA for the company is -380.21 million with net debt to EBITDA at 0.2. When we switch over and look at the enterprise to sales, we see a ratio of 51.21. The liquidity ratio also appears to be rather interesting for investors as it stands at 15.95.
Conclusion
To wrap up, the performance of Relay Therapeutics Inc (RLAY) has been bad in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
